KRAS mutation: from undruggable to druggable in cancer
Abstract Cancer is the leading cause of death worldwide, and its treatment and outcomes have been dramatically revolutionised by targeted therapies. As the most frequently mutated oncogene, Kirsten rat sarcoma viral oncogene homologue (KRAS) has attracted substantial attention. The understanding of...
Guardado en:
Autores principales: | Lamei Huang, Zhixing Guo, Fang Wang, Liwu Fu |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/376e4538053644209dbda716fe11e25a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Targeting the undruggable: an interview with Leila Akkari on fighting cancer by rewiring cells
Publicado: (2021) -
Target inhibition networks: predicting selective combinations of druggable targets to block cancer survival pathways.
por: Jing Tang, et al.
Publicado: (2013) -
Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer
por: Giorgia Maroni, et al.
Publicado: (2021) -
Mutational burden and chromosomal aneuploidy synergistically predict survival from radiotherapy in non-small cell lung cancer
por: Qingzhu Jia, et al.
Publicado: (2021) -
Using CRISPR to understand how cancer mutations happen
por: Eve H. Rogers
Publicado: (2021)